Communiqués Ovid Therapeutics Inc.

Actions

OVID

US6904691010

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 07/10/2026			Varia. 5j.	Varia. 1 janv.
2,360 ^USD	-0,42 %		-7,09 %	+44,79 %

06/10	Ovid Therapeutics Inc. : Guggenheim maintient sa recommandation à l'achat	ZM
13/08	Ovid Therapeutics fait le point sur son pipeline et ses activités	CI

Communiqués

04/09	Ovid Therapeutics to Participate in Upcoming Investor Conferences	AQ
03/09	Ovid Therapeutics to Participate in Upcoming Investor Conferences	GL
13/08	Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results	GL
08/07	Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development	GL
04/06	Ovid Therapeutics to Participate in Upcoming Investor Conferences	GL
03/06	Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors	GL
03/06	Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors	AQ
12/05	Ovid Therapeutics : May 2026 Corporate Presentation	PU
12/05	Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results	GL
14/04	Ovid Therapeutics : KCC2 Deep Dive Day	PU
08/04	Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14	GL
08/04	Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14	AQ
18/03	Ovid Therapeutics : Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results	PU
18/03	Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results	GL
18/03	Ovid Therapeutics Announces Pricing of $60 Million Private Placement	GL
25/02	Ovid Therapeutics to Participate in Upcoming Investor Conferences	GL
13/01	Ovid Therapeutics : January 2026 Corporate Presentation	PU
19/12	Ovid Therapeutics Reports Phase 1 results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2, OV350 Intravenous	AQ
18/12	Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)	GL
02/12	Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer	GL
14/11	Ovid Therapeutics : November 2025 Corporate Presentation	PU
12/11	Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results	GL
12/11	Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results	AQ
03/10/25	Ovid Therapeutics : OV329 Topline Data Presentation	PU
03/10/25	Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds	GL